Phase 3 Clinical Trials
The study your entire program has been building toward. We run multi-site Phase III trials across a pan-India investigator network — recruitment, monitoring, data management, and biostatistics under one accountable partner.
Participants
Site Network
Under NDCT 2019
Compliant
What Is a Phase 3 Clinical Trial?
A Phase 3 clinical trial is the large confirmatory study — typically 300 to 3,000 patients across multiple sites — that tests whether a treatment works safely at scale, usually against placebo or the current standard of care. It is the pivotal evidence regulators review when deciding on marketing approval, which is why Phase III carries most of a program’s budget and most of its risk.
That risk is operational as much as scientific. A Phase III program succeeds or fails on execution: sites that activate on schedule, recruitment that reaches target without compromising eligibility, monitoring that catches problems while they are still small, and a data pipeline clean enough that database lock is an event, not an ordeal.
We manage Phase III trials end to end through a pan-India network of experienced investigators and sites, under ICH-GCP E6 (R3) with independent ethics oversight. India’s New Drugs and Clinical Trials Rules, 2019 give sponsors defined review timelines, and the country’s large, diverse patient pool shortens recruitment — the two reasons global programs increasingly place pivotal studies here. Sponsors get one accountable partner across Phase I–IV, from protocol to final statistical report.
The study — almost always Phase III — whose results carry the approval decision. Its design is agreed with regulators in advance, and its efficacy and safety data form the core of the marketing application.
India’s New Drugs and Clinical Trials Rules under CDSCO: clinical trial applications are reviewed by DCGI within defined timelines — 90 working days as standard, 30 for drugs discovered or developed in India — with registered ethics committees and CTRI registration required.
Phase 2 vs Phase 3 vs Phase 4 — What Changes at Each Step
Three phases, three different questions. Phase III proves the treatment works at scale; Phase IV watches it perform in the real world.
| Aspect | Phase II | Phase III | Phase IV |
|---|---|---|---|
| Primary question | Does the drug work, and at what dose? | Does it work at scale, safely, versus standard care? | How does it perform in real-world use after approval? |
| Typical size | Around 100–300 patients | 300–3,000 patients | Several hundred to many thousands of patients |
| Setting | A limited number of sites | Large multi-site programs, often multi-country | Routine clinical practice across marketed geographies |
| Duration | Several months to around two years | Commonly one to four years | Ongoing — tied to surveillance and PSUR obligations |
| Regulatory role | Dose selection and proof of concept | The pivotal evidence base for marketing approval | Post-approval safety commitments and label evolution |
| Outcome | Go/no-go into pivotal development | Marketing authorization submission | Continued safety data, real-world evidence, new indications |
What We Run for a Phase III Program
Six service lines, one accountable team — so no problem falls between vendors.
Site Selection & Activation
Sites chosen from our pan-India network on real capability and patient access, activated on a managed timeline.
Patient Recruitment & Retention
Targeted recruitment plans and retention programs that hit enrolment targets without diluting eligibility.
Clinical Monitoring
Risk-proportionate on-site and centralised monitoring that finds issues while they are still correctable.
Medical Monitoring & Safety
Continuous medical oversight, adverse event workflows, and disciplined reporting to ethics and regulators.
Data Management
Validated data capture and cleaning that keeps the database current — so lock is a date, not a struggle.
Biostatistics & Reporting
Statistical analysis plans, interim and final analyses, and outputs ready for the clinical study report.
Why Global Sponsors Run Phase III in India
Recruitment is the schedule risk in every pivotal trial, and India’s patient pool is the answer: a large, genetically and geographically diverse population across therapeutic areas, concentrated around experienced investigator sites. The NDCT Rules, 2019 added the other half — defined DCGI review timelines and registered ethics committees — making India as predictable on paper as it is fast on the ground. Our division brings 70+ years of cumulative team experience and 150+ projects under execution to that landscape.
Why Sponsors Choose Us for Phase III Trials
- Pan-India investigator and site network across therapeutic areas
- ICH-GCP E6 (R3) conduct with independent ethics oversight
- Recruitment planning built on India’s deep, diverse patient pool
- Single accountable partner from protocol to statistical report
- In-house data management, biostatistics, and medical writing
- NDCT Rules 2019 fluency — predictable submissions and timelines
Phase III Trials — Frequently Asked Questions
1. What are the 4 phases of clinical trials?
2. How many patients are needed for a phase 3 clinical trial?
3. What is the difference between phase 3 and phase 4 clinical trials?
4. How long does a phase 3 clinical trial take?
5. How are phase 3 trials approved and regulated in India?
6. What happens after a phase 3 trial succeeds?
7. Can you manage a multi-country phase 3 trial from India?
More Patient-Based Clinical Trials Services
Every study type under one roof — explore the rest of our patient-based clinical trials capabilities.
Discuss Your Phase III Trials Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.